Shares of companies developing treatments based on psilocybin and other psychedelic drugs moved lower on Monday after the U.S. Food and Drug Administration rejected use of MDMA for post-traumatic stress disorder.
More Stories
Dow surges to record as investors celebrate Fed’s ‘recalibration’ rate cut
Fed Chair Jerome Powell emphasized a policy “recalibration.” Investors like the sound of it.
Fed is more worried about labor market than Powell let on, William Dudley says
Federal Reserve Chair Jerome Powell did a “great job” of explaining the reasons for an aggressive interest-rate cut in a...
FedEx stock falls as company narrows its full-year forecast
The package-delivery giant said reduced demand for priority services and higher operating costs weighed on results.
Nike taps company veteran as new CEO, and shares rally
Elliott Hill will replace John Donahoe as chief executive next month, following months of struggles for the athletic-wear giant.
Mortgage rates went up right after the Fed cut interest rates. Here’s why.
Mortgage rates inched up even though the Federal Reserve cut interest rates. Experts explain why this is a short-lived phenomenon.
Trump’s cap for credit-card interest rates wouldn’t pass Congress, analyst says
Republican presidential nominee Donald Trump on Wednesday promised to cap interest rates for credit cards, but a veteran analyst predicts...